TAPIR: CRISPR Tool for Controlling Cellular Protein Production

Researchers led by Professor Stefan H. Stricker at LMU Munich have developed a groundbreaking CRISPR-based tool called TAPIR (Targeted Activation of Protein Translation). Published in Science on July 16, 2026, this technology allows scientists to precisely increase ribosomal RNA (rRNA) production, providing a direct method to manipulate cellular protein synthesis and study its causal role in development and disease. The study challenges the traditional view of rRNA as a passive component, demonstrating that it actively drives protein production. By using TAPIR, the team proved that modulating rRNA levels can either compensate for genetic defects in ribosomopathies or accelerate the growth of aggressive tumors, depending on the biological context. This research establishes protein biosynthesis as a critical therapeutic target. The ability to selectively control rRNA activity offers a new platform for investigating cell identity and growth, potentially leading to future treatments for conditions ranging from rare congenital disorders to cancer. For the scientific community, TAPIR serves as a versatile research instrument to dissect the mechanisms of protein translation. Users can apply this tool to explore how specific disease states rely on protein output, helping to identify whether increasing or inhibiting rRNA activity is the appropriate strategy for therapeutic intervention.